(Q34999400)

5 August 2017

1 reference

title

Adjuvant therapy in colon cancer: current status and future directions (English)

1 reference

5 August 2017

1 reference

2

David Cunningham

1 reference

5 August 2017

Ian Chau

1

1 reference

5 August 2017

publication date

1 October 2002

1 reference

5 August 2017

published in

Cancer Treatment Reviews

1 reference

5 August 2017

volume

28

1 reference

5 August 2017

issue

5

1 reference

5 August 2017

page(s)

223-236

1 reference

Follow-up of patients with colorectal cancer: numbers needed to test and treat

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900047-6

7 January 2021

Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900047-6

7 January 2021

Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900047-6

7 January 2021

Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900047-6

7 January 2021

Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900047-6

7 January 2021

Adjuvant therapy of Dukes' A, B, and C adenocarcinoma of the colon with portal-vein fluorouracil hepatic infusion: preliminary results of National Surgical Adjuvant Breast and Bowel Project Protocol C-02

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900047-6

7 January 2021

The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900047-6

7 January 2021

Adjuvant 5-fluorouracil and leucovorin with or without interferon alfa-2a in colon carcinoma: National Surgical Adjuvant Breast and Bowel Project protocol C-05.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900047-6

7 January 2021

Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900047-6

7 January 2021

Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900047-6

7 January 2021

Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900047-6

7 January 2021

Fluorouracil plus leucovorin as effective adjuvant chemotherapy in curatively resected stage III colon cancer: results of the trial adjCCA-01.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900047-6

7 January 2021

Toxicity and effects of adjuvant therapy in colon cancer: results of the German prospective, controlled randomized multicenter trial FOGT-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900047-6

7 January 2021

Adjuvant chemotherapy with 5-fluorouracil, L-folinic acid and levamisole for patients with colorectal cancer: non-randomised comparison of weekly versus four-weekly schedules--less pain, same gain. QUASAR Colorectal Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900047-6

7 January 2021

Age and adjuvant chemotherapy use after surgery for stage III colon cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900047-6

7 January 2021

A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900047-6

7 January 2021

Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900047-6

7 January 2021

Outcomes among African-Americans and Caucasians in colon cancer adjuvant therapy trials: findings from the National Surgical Adjuvant Breast and Bowel Project

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900047-6

7 January 2021

Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900047-6

7 January 2021

Should Dukes' B patients receive adjuvant therapy? A statistical perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900047-6

7 January 2021

Prognostic evaluation of stage B colon cancer patients is improved by an adequate lymphadenectomy: results of a secondary analysis of a large scale adjuvant trial

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900047-6

7 January 2021

Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900047-6

7 January 2021

Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900047-6

7 January 2021

Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900047-6

7 January 2021

Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900047-6

7 January 2021

Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900047-6

7 January 2021

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900047-6

7 January 2021

Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900047-6

7 January 2021

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900047-6

7 January 2021

Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900047-6

7 January 2021

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900047-6

7 January 2021

Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900047-6

7 January 2021

Mortality associated with irinotecan plus bolus fluorouracil/leucovorin

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900047-6

7 January 2021

Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900047-6

7 January 2021

Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900047-6

7 January 2021

Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900047-6

7 January 2021

Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900047-6

7 January 2021

Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900047-6

7 January 2021

Molecular predictors of survival after adjuvant chemotherapy for colon cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900047-6

7 January 2021

Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900047-6

7 January 2021

Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900047-6

7 January 2021

Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900047-6

7 January 2021

Surgical management of hepatic metastases from colorectal malignancies.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900047-6

7 January 2021

Postsurgical surveillance of colon cancer: preliminary cost analysis of physician examination, carcinoembryonic antigen testing, chest x-ray, and colonoscopy

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900047-6

7 January 2021

Surveillance for second primary colorectal cancer after adjuvant chemotherapy: an analysis of Intergroup 0089.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900047-6

7 January 2021

Value and cost of follow-up after adjuvant treatment of patients with Dukes' C colonic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900047-6

7 January 2021

National Surgical Adjuvant Breast and Bowel Project trials in colon cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900047-6

7 January 2021

Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900047-6

7 January 2021

Efficacy of adjuvant fluorouracil and leucovorin in stage B2 and C colon cancer. International Multicenter Pooled Analysis of Colon Cancer Trials Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900047-6

7 January 2021

10.1016/S0305-7372(02)00047-6

Identifiers

DOI

1 reference

5 August 2017

1 reference